Elan falls 12pc despite Tysabri nod

Unison.ie - Bray,Ireland
SHARES in the Irish pharmaceutical group Elan fell sharply in New York last night on the back of fears that sales of its MS drug Tysabri would fall below ...

Biogen Wins US Approval to Resume Sales of Tysabri (Update3)
Bloomberg - USA
June 5 (Bloomberg) -- US regulators approved the return of the multiple sclerosis drug Tysabri, withdrawn last year by Biogen Idec Inc. and Elan Corp. ...

Mullen's Biogen Gets FDA OK On Tysabri; Investors Wary
Forbes - USA
... In Feb. 2005, Biogen agreed to pull from the market its drug Tysabri, prescribed to help control relapsing-MS flare-ups, which can hamper walking and seeing. ...

Elan says Tysabri could still take up to 60% of MS drug market
MarketWatch - USA
PLC (ELN) on Monday remained hopeful that its multiple sclerosis drug Tysabri could take up to 60% of the MS market, despite the US Food & Drug ...

Elan, Biogen slide on Tysabri news
MarketWatch - USA
... Idec slid on Monday after they announced that while the Food and Drug Administration has ruled to allow its recalled multiple sclerosis drug Tysabri back on ...